Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOTOX for Primary Fascial Closure in Ventral Hernia Repair
NCT05606757Phase 2Withdrawn
- Sponsor
- AbbVie Inc.
- Start
- May 2024
- Primary completion
- Apr 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of botulinum toxin type A in ventral hernia, sponsored by AbbVie Inc.. Planned start May 2024; status: withdrawn.
02
Drugs
botulinum toxin type A
03
Conditions
ventral hernia
Beyond the preview
Go deeper on NCT05606757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05606757.